Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature

References

• Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018
   PubMed Web of Science ®Google Scholar
• Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):1801913. doi:10.1183/13993003.01913-2018
   PubMed Web of Science ®Google Scholar
• Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension. J Investig Med. 2021;69:1270–1280. doi:10.1136/jim-2021-002027
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tamosiuniene R, Nicolls MR. Challenges and opportunities in treating inflammation associated with pulmonary hypertension. Expert Rev Cardiovasc Ther. 2016;14(8):939–951. doi:10.1080/14779072.2016.1180976
   PubMed Web of Science ®Google Scholar
• Chami H, Hassoun PM. Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension. Compr Physiol. 2011;1:1929–1941.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175. doi:10.1161/CIRCRESAHA.113.301141
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40:1555–1565. doi:10.1183/09031936.00046612
   PubMed Web of Science ®Google Scholar
• Huertas A, Tu L, Humbert M, Guignabert C. Chronic inflammation within the vascular wall in pulmonary arterial hypertension: more than a spectator. Cardiovasc Res. 2020;116:885–893. doi:10.1093/cvr/cvz308
   PubMed Web of Science ®Google Scholar
• Xiao Y, Chen PP, Zhou RL, Zhang Y, Tian Z, Zhang SY. Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review. Aging Dis. 2020;11(6):1623–1639. doi:10.14336/AD.2020.0111
   PubMed Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53:1801887. doi:10.1183/13993003.01887-2018
   PubMed Web of Science ®Google Scholar
• Cohen-Kaminsky S, Hautefort A, Price L, Humbert M, Perros F. Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. Drug Discov Today. 2014;19(8):1251–1256. doi:10.1016/j.drudis.2014.04.007
   PubMed Web of Science ®Google Scholar
• Frid MG, Thurman JM, Hansen KC, Maron BA, Stenmark KR. Inflammation, immunity, and vascular remodeling in pulmonary hypertension; Evidence for complement involvement? Glob Cardiol Sci Pract. 2020;2020:e202001. doi:10.21542/gcsp.2020.1
   PubMedGoogle Scholar
• Perros F, Dorfmuller P, Montani D. Montani, D Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185:311–321. doi:10.1164/rccm.201105-0927OC
   PubMed Web of Science ®Google Scholar
• Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol. 2015;31:407–415. doi:10.1016/j.cjca.2014.10.023
   PubMed Web of Science ®Google Scholar
• Fujita M, Mason RJ, Cool C, et al. Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol. 1985;2002(93):2162–2170.
   Google Scholar
• Liu D, Wu WH, Mao YM, et al. BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012;5:511–518. doi:10.1161/CIRCGENETICS.111.962209
   PubMedGoogle Scholar
• Graf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9:1416. doi:10.1038/s41467-018-03672-4
   PubMed Web of Science ®Google Scholar
• Burton VJ, Ciuclan LI, Holmes AM, Rodman DM, Walker C, Budd DC. Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood. 2011;117:333–341. doi:10.1182/blood-2010-05-285973
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436. doi:10.1056/NEJMra040291
   PubMed Web of Science ®Google Scholar
• Lindemann S, Gierer C, Darius H. Prostacyclin inhibits adhesion of polymorph nuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol. 2003;98(1):8–15. doi:10.1007/s00395-003-0383-1
   PubMed Web of Science ®Google Scholar
• Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6–30. doi:10.1111/bph.15016
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G; Aerosolized Iloprost Randomized Study Group, et al. Inhaled Iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257–1263. doi:10.1164/rccm.200603-358OC
   PubMed Web of Science ®Google Scholar
• Klinger JR, Abman SH, Gladwin MT. Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2013;188:639–646. doi:10.1164/rccm.201304-0686PP
   PubMed Web of Science ®Google Scholar
• Kniotek M, Boguska A. Sildenafil can affect innate and adaptive immune system in both experimental animals and patients. J Immunol Res. 2017;2017:4541958. doi:10.1155/2017/4541958
   PubMed Web of Science ®Google Scholar
• Toxvig AK, Wehland M, Grimm D, Infanger M, Krüger M. A focus on riociguat in the treatment of pulmonary arterial hypertension. Basic Clin Pharmacol Toxicol. 2019;125(3):202–214. doi:10.1111/bcpt.13272
   PubMed Web of Science ®Google Scholar
• Klouda T, Yuan K. Inflammation in pulmonary arterial hypertension. Adv Exp Med Biol. 2021;1303:351–372.
   PubMed Web of Science ®Google Scholar
• Kumar R, Graham B. How does inflammation contribute to pulmonary hypertension? Eur Respir J. 2018;51:1702403. doi:10.1183/13993003.02403-2017
   PubMed Web of Science ®Google Scholar
• Meloche J, Renard S, Provencher S, Bonnet S. Anti-inflammatory and immunosuppressive agents in PAH. Handb. Exp. Pharmacol. 2013;218:437–476.
   PubMedGoogle Scholar
• Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2021;204(2):209–221. doi:10.1164/rccm.202009-3481OC
   PubMed Web of Science ®Google Scholar
• Trankle CR, Canada JM, Kadariya D, et al. IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single- arm, open-label, phase IB/II pilot study. Am J Respir Crit Care Med. 2019;199:381–384. doi:10.1164/rccm.201809-1631LE
   PubMed Web of Science ®Google Scholar
• Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384:1204–1215. doi:10.1056/NEJMoa2024277
   PubMed Web of Science ®Google Scholar